Wilson Sonsini Advises Novo Holdings on Route 92 Medical’s $50 Million Growth Financing

"Wilson Sonsini Goodrich & Rosati advised Novo Holdings on Route 92 Medical’s $50 million growth financing. The round was led by Novo Holdings and included new investor Sectoral Asset Management alongside existing investors U.S. Venture Partners, Norwest Venture Partners, InnovaHealth Partners and The Vertical Group."

Wilson Sonsini Goodrich & Rosati advised Novo Holdings on the transaction involving Route 92 Medical. On April 7, 2026, Route 92 Medical, a privately held medical technology company focused on improving outcomes for patients undergoing neurovascular intervention, announced a $50 million growth financing. The financing round was led by Novo Holdings and included participation from new investor Sectoral Asset Management as well as existing investors U.S. Venture Partners, Norwest Venture Partners, InnovaHealth Partners and The Vertical Group. Wilson Sonsini Goodrich & Rosati represented Novo Holdings with a team composed by: Danielle Naftulin, Tamara Labanowski, and Emily Gottfredson.

Menu

Wilson Sonsini Advises Novo Holdings on Route 92 Medical’s $50 Million Growth Financing

Read the full story

Menu

Wilson Sonsini Advises Novo Holdings on Route 92 Medical’s $50 Million Growth Financing

Read the full story

Cookie Preferences

Strictly Necessary

Analytics & Statistics

Marketing & Ads